top of page

Lundbeck acquired Abide Therapeutics and their lead compound ABX-1431

  • Writer: ipharmaservices
    ipharmaservices
  • Jun 1, 2019
  • 1 min read

Updated: Jun 3, 2019

Lundbeck has completed the acquisition of US-based biotech company Abide Therapeutics and the lead compound ABX-1431.



On May 6th, 2019 Lundbeck announced that it was acquiring Abide Therapeutics. Abide Therapeutics is currently working the serine hydrolases; the acquisition helps

Lundbeck to work on new classes of drugs for a range of therapeutic activities.


Also, Lundbeck gets the advanced compound ABX-1431 first-in-class MAG Lipase inhibitor used for the treatment of Tourette Syndrome and neuropathic pain.

Recent Posts

See All

Comments


For sponsored articles, link insertions, and advertisements, please write to info@ipharmacenter.com

Find the latest pharma and healthcare news on Telegram now. Simply scan the QR code. 

Rephrase with Ginger (Cmd+⌥+E)
iPharmaCenter Telegran_edited.jpg
bottom of page